Recent progress in enzymatic resolution and desymmetrization of pharmaceuticals and their intermediates.
The literature since August 2000 is surveyed for interesting and useful examples of the resolution or desymmetrization of pharmaceutical entities, their intermediates and potential drug precursors. Existing, putative and developmental drugs used in various therapeutic areas are discussed.
Pesti
Jaan A
JA
Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543-4000, USA. jaan.pesti@bms.com
DiCosimo
Robert
R
D004789:Enzyme Activation; D006571:Heterocyclic Compounds / Q000138:chemical synthesis; D004364:Pharmaceutical Preparations / Q000138:chemical synthesis*; D011355:Prodrugs / Q000138:chemical synthesis*; D013237:Stereoisomerism; D013678:Technology, Pharmaceutical / Q000639:trends*
D006571:Heterocyclic Compounds; D004364:Pharmaceutical Preparations; D011355:Prodrugs